Physician profile
Ross Stemmler
NPI 1164816559
$2,451.79
in general payments reported to CMS, 2019-2025
33 companies · $52.89 in 2025
The $52.89 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $554 · 2021: $537 · 2022: $12.34 · 2025: $52.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $559.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $178.33 | 2019-2025 | Breztri |
| Amgen INC. | $155.72 | 2019-2021 | |
| Amarin Pharma, INC. | $146.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.45 | 2019-2020 | |
| Lilly USA, LLC | $108.64 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.78 | 2019 | |
| Pfizer INC. | $90.48 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $85.09 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $73.63 | 2019-2020 | |
| Esperion Therapeutics, INC. | $66.48 | 2021 | |
| Abbvie INC. | $57.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.61 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $40.03 | 2019 | |
| Ironwood Pharmaceuticals, INC | $37.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.60 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.19 | 2019 | |
| Daiichi Sankyo INC. | $19.79 | 2019 | |
| Genzyme Corporation | $17.92 | 2019 | |
| Dynavax Technologies Corporation | $17.47 | 2019 | |
| Allergan, INC. | $17.11 | 2020 | |
| Almatica Pharma LLC | $16.23 | 2021 | |
| Grifols USA, LLC | $15.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.62 | 2021 | |
| Currax Pharmaceuticals LLC | $13.71 | 2019 | |
| Biodelivery Sciences International, INC. | $13.01 | 2020 | |
| Gilead Sciences, INC. | $12.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.34 | 2022 | |
| Optinose US, INC. | $12.03 | 2021 | |
| Merck Sharp & Dohme LLC | $11.11 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Stemmler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.